AAK1 Inhibitor Dihydrogen Phosphate Crystalline Form for Scale-Up

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing synthetic approaches for the AAK1 inhibitor (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine are not suitable for large-scale manufacture due to issues with byproduct formation, use of toxic solvents, and inefficient or dangerous reaction conditions.

Innovation Solution

Development of stable pharmaceutically acceptable salts, particularly the dihydrogen phosphate salt, which can be manufactured on a large scale with high purity, and the identification of a thermally stable crystalline form suitable for pharmaceutical dosage forms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If existing synthetic approaches are used for the AAK1 inhibitor, then the compound can be prepared on a small laboratory scale, but the process is not suitable for large-scale manufacture due to byproduct formation, toxic solvents, and dangerous reaction conditions

Engineering Contradiction:

Improvesuitability for large-scale manufactureVSAvoidbyproduct formation, toxic solvents, dangerous reaction conditions

Core Design Contradiction:

Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying reaction conditions including temperature, pressure, solvent selection, and stoichiometry to transform a laboratory-scale synthesis into a scalable manufacturing process. The optimized parameters eliminate harmful byproducts and replace toxic solvents while maintaining high yields of the AAK1 inhibitor

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts potentially harmful reaction byproducts into beneficial outcomes by optimizing reaction pathways to minimize unwanted side reactions. The process transforms a hazardous synthesis into a safe, scalable manufacturing process by eliminating toxic intermediates and using environmentally benign solvents

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If amorphous forms of the compound are used, then pre-clinical testing can be conducted, but the forms are not suitable for large scale manufacture and storage due to stability issues

Engineering Contradiction:

Improvestability for manufacture and storageVSAvoiddecomposition under heat and moisture

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies phase transitions by transforming the compound from an amorphous state to a crystalline solid form. This phase change provides enhanced thermal and moisture stability, enabling large-scale manufacture and long-term storage while maintaining pharmaceutical quality. The crystalline structure resists decomposition that plagues amorphous forms

Inventive Principle:

Principle #36Phase transitions

Data Source

PatentUS12344596B2Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof

Publication Date: 2025.07.01 LEXICON PHARMACEUTICALS INC

AI summary

Salts of the AAK1 inhibitor (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and solid forms thereof are disclosed, as are pharmaceutical formulations comprising them and methods of their preparation.